Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.57 |
| ▸ | TSHR | P16473 | 6/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | SLC22A1 | O15245 | 3/20 | 0.37 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | DNM1 | Q05193 | 5/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hexane SCHEMBL10697149 | 1.00 | ALDH1A1 (0.57) | ALDH1A1TSHRTHRBTDP1LMNA | |
| Hexane SCHEMBL10428089 | 0.97 | ALDH1A1 (0.53) | ALDH1A1TSHRTHRBTDP1LMNA | |
| Heptane SCHEMBL114510 | 0.97 | TSHR (0.53) | ALDH1A1TSHRTHRBTDP1LMNA | |
| Pentane SCHEMBL1230691 | 0.93 | ALDH1A1 (0.57) | ALDH1A1TSHRTHRBTDP1LMNA | |
| Hexane SCHEMBL9152574 | 0.91 | ALDH1A1 (0.47) | ALDH1A1TSHRTHRBTDP1LMNA | |
| Hexane SCHEMBL27545868 | 0.91 | ALDH1A1 (0.47) | ALDH1A1TSHRTHRBTDP1LMNA | |
| Heptane SCHEMBL8040709 | 0.88 | TSHR (0.48) | ALDH1A1TSHRTHRBTDP1LMNA | |
| 1-Pentanol SCHEMBL3231040 | 0.86 | SMN1; SMN2 (0.63) | ALDH1A1TSHRTHRBTDP1LMNA | |
| Hexane SCHEMBL8597024 | 0.86 | ALDH1A1 (0.42) | ALDH1A1TSHRTHRBTDP1LMNA | |
| Hexane SCHEMBL10705929 | 0.86 | ALDH1A1 (0.42) | ALDH1A1TSHRTDP1HSD17B10MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 656 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104250212-A | Method for preparing highly pure danshinolic acid A | WUXI TARGET DRUG RES CO LTD | 2014-12-31 | — | — | CN | claimed |
| CN-1389459-A | Optical breaking process of d1-trans-4-phenyl-5-O-chlorobenzyl pyrrolidone-2 | KUNMING INST BOTANY CN ACAD (CN) | 2003-01-08 | — | — | CN | claimed |
| US-12018093-B2 | Hemiasterlin derivatives and antibody-drug conjugates including same | Sumitomo Pharma Co., Ltd. (JP) | 2024-06-25 | — | — | US | disclosed |
| CN-118184532-A | Amino acid having functional group capable of forming intramolecular hydrogen bond, peptide compound containing the amino acid, and process for producing the same | 中外制药株式会社 | 2024-06-14 | — | — | CN | disclosed |
| US-20240150389-A1 | MODIFIED GUANINES | NUCLERA LTD (GB) | 2024-05-09 | — | — | US | disclosed |
| US-RE49948-E1 | Aryl ethers and uses thereof | PELOTON THERAPEUTICS, INC. (US) | 2024-04-30 | — | — | US | disclosed |
| CN-113454058-B | Amino acid having functional group capable of forming intramolecular hydrogen bond, peptide compound containing the amino acid, and process for producing the same | 中外制药株式会社 | 2024-03-22 | — | — | CN | disclosed |
| US-20240059636-A1 | PROCESS OF MAKING ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2024-02-22 | — | — | US | disclosed |
| US-20240059732-A1 | Antibody-Drug Conjugates Including Hemiasterlin Derivative | Sumitomo Pharma Co., Ltd. (JP) | 2024-02-22 | — | — | US | disclosed |
| EP-3666787-B1 | ANTIBODY-DRUG CONJUGATES INCLUDING HEMIASTERLIN DERIVATIVE | SUMITOMO PHARMA CO LTD (JP) | 2024-02-21 | — | — | EP | disclosed |
| EP-4321523-A2 | HEMIASTERLIN DERIVATIVES AND ANTIBODY-DRUG CONJUGATES INCLUDING SAME | Sumitomo Pharma Co., Ltd. (JP) | 2024-02-14 | — | — | EP | disclosed |
| CN-87106830-A | TERTIARY AMINE COMPOUND | — | 1988-06-29 | — | — | CN | disclosed |
| EP-0259977-A2 | Tertiary amine compounds | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1988-03-16 | — | — | EP | disclosed |
| US-4709030-A | 4-ALKENYL OR 2Z-ALKENYL POLYPHENYL COMPOUNDS; ELECTRO-OPTICS | HOFFMANN-LA ROCHE INC. (US) | 1987-11-24 | — | — | US | disclosed |
| US-4696766-A | FRAGRANCES | GIVAUDAN CORPORATION (US) | 1987-09-29 | — | — | US | disclosed |
| US-4684636-A | Antiandrogenic sulfonylsteroidopyrazoles and processes for preparation method of use and compositions thereof | STERLING DRUG INC. (US) | 1987-08-04 | — | — | US | disclosed |
| EP-0207375-A1 | Steroido [3,2-c] pyrazoles useful as antiandrogenic agents and preparation thereof | STERLING DRUG INC. (US) | 1987-01-07 | — | — | EP | disclosed |
| EP-0203528-A2 | Cyclopentene derivatives and their use as odorants | L. GIVAUDAN & CIE Société Anonyme (CH) | 1986-12-03 | — | — | EP | disclosed |
| US-4621901-A | ELECTROOPTICS | HOFFMANN-LA ROCHE INC. (US) | 1986-11-11 | — | — | US | disclosed |
| EP-0141608-A2 | Pyrazolopyridine cycloalkanone derivatives | ICI AMERICAS INC. (US) | 1985-05-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240150389-A1 | MODIFIED GUANINES | NSUN2, RNMT, RNGTT | ALDH1A1 1116/4885TSHR 2171/4885THRB 2961/4885 |
| US-20240059636-A1 | PROCESS OF MAKING ORGANIC COMPOUNDS | POR, CYC1, CYP11B1 | ALDH1A1 200/4885TSHR 4853/4885THRB 4693/4885 |
| US-20240059732-A1 | Antibody-Drug Conjugates Including Hemiasterlin Derivative | HSD3B2, HSD3B1, HSD11B2 | ALDH1A1 1287/4885TSHR 1852/4885THRB 2266/4885 |
| US-12018093-B2 | Hemiasterlin derivatives and antibody-drug conjugates including same | FCGRT, QARS1, INHA | ALDH1A1 1215/4885TSHR 1863/4885THRB 2138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.